HomeCompareSTRCW vs PFE

STRCW vs PFE: Dividend Comparison 2026

STRCW yields 4000.00% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 STRCW wins by $7175340620755.82M in total portfolio value
10 years
STRCW
STRCW
● Live price
4000.00%
Share price
$0.05
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$7175340620755.87M
Annual income
$6,839,006,593,197,835,000.00
Full STRCW calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — STRCW vs PFE

📍 STRCW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSTRCWPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, STRCW + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
STRCW pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

STRCW
Annual income on $10K today (after 15% tax)
$340,000.00/yr
After 10yr DRIP, annual income (after tax)
$5,813,155,604,218,160,000.00/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, STRCW beats the other by $5,813,155,604,218,138,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of STRCW + PFE for your $10,000?

STRCW: 50%PFE: 50%
100% PFE50/50100% STRCW
Portfolio after 10yr
$3587670310377.96M
Annual income
$3,419,503,296,598,931,000.00/yr
Blended yield
95.31%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

STRCW
Analyst Ratings
3
Hold
Consensus: Hold
Altman Z
-7.3
Piotroski
3/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

STRCW buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSTRCWPFE
Forward yield4000.00%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$7175340620755.87M$49.6K
Annual income after 10y$6,839,006,593,197,835,000.00$26,258.71
Total dividends collected$7152397773804.84M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldHold

Year-by-year: STRCW vs PFE ($10,000, DRIP)

YearSTRCW PortfolioSTRCW Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$410,700$400,000.00$9,153$693.39+$401.5KSTRCW
2$15,792,720$15,353,271.03$8,593$849.25+$15.78MSTRCW
3$568,657,142$551,758,931.89$8,336$1,066.78+$568.65MSTRCW
4$19,176,207,860$18,567,744,718.20$8,437$1,384.80+$19176.20MSTRCW
5$605,696,028,890$585,177,486,479.73$9,013$1,875.40+$605696.02MSTRCW
6$17,922,210,653,594$17,274,115,902,681.27$10,306$2,680.72+$17922210.64MSTRCW
7$496,869,793,504,300$477,693,028,104,954.00$12,820$4,101.38+$496869793.49MSTRCW
8$12,908,672,105,251,704$12,377,021,426,202,104.00$17,673$6,826.70+$12908672105.23MSTRCW
9$314,330,866,876,668,540$300,518,587,724,049,200.00$27,543$12,591.86+$314330866876.64MSTRCW
10$7,175,340,620,755,871,000$6,839,006,593,197,835,000.00$49,560$26,258.71+$7175340620755.82MSTRCW

STRCW vs PFE: Complete Analysis 2026

STRCWStock

Sarcos Corp., a robotics and sensor company, designs, builds, and produces dexterous tele-operated robotic systems. Its products include Guardian S, an unmanned ground vehicle for security, inspection, and non-destructive testing available in a Robot-as-a-Service offering; Guardian GT, a big arm system or dual-armed human-controlled robot mounted on an agile tracked vehicle base for commercial, industrial, and first responder environments; and Guardian XO, a robot that features an exoskeleton suit; SenSuit controller garment for enhanced teleoperation of the Guardian XT (a highly dexterous mobile robotic system); and humanoid solutions. The company also provides advanced robotic systems for industry, entertainment; medical devices, including artificial limbs and vascular systems; and mechanical and electrical microsystems for practical applications. The company serves healthcare, life sciences, telecommunications, robotics, defense, and entertainment industries. Sarcos Corp. was founded in 1983 and is based in Salt Lake City, Utah with an additional office in Bellevue, Washington. Sarcos Corp. is a former subsidiary of Raytheon Company.

Full STRCW Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this STRCW vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

STRCW vs SCHDSTRCW vs JEPISTRCW vs OSTRCW vs KOSTRCW vs MAINSTRCW vs JNJSTRCW vs MRKSTRCW vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.